ClinicalTrials.gg
CompletedNCT06264310Updated Jun 22, 2026

To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

A Phase 2 interventional study of Placebo and R2R01 in Heart Failure and Worsening Heart Failure (WHF), sponsored by River 2 Renal Corp.. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by River 2 Renal Corp. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.

Enrollment
1,046th of 1,601
33 · median 65
Started
2024
with 107 others
Phase 2
227 of 2,157
26 open now
Registered
1,883rd of 2,157
by date

Among the 2,157 studies in Heart Failure with a site in United States, this one is the 1,046th largest by enrollment of the 1,601 interventional ones that give a count, is one of 108 that started in 2024, is one of 227 in phase 2, and was the 1,883rd registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,157 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

This Study Aims to Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

Read the detailed description

This is a Phase 2, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 combined with Standard of Care versus Standard of Care Alone in Outpatients with Worsening Heart Failure (WHF). Each patient will undergo a screening period of up to 21 days, an active treatment period of 7 days, and a follow up period of 23 days after the last dose (30 days after the first dose), i.e., a total of up to 51 days total study duration.

This study is a four-parallel-cohort study. All patients will be randomized to one of the following Cohorts:

  1. Cohort 1 (N=8): Placebo once daily SC for 7 days.
  2. Cohort 2 (N=8): 5.0 mg R2R01 once daily SC for 7 days.
  3. Cohort 3 (N=8): 7.5 mg R2R01 once daily SC for 7 days.
  4. Cohort 4 (N=8): 10.0 mg R2R01 once daily SC for 7 days. All patients will present with worsening heart failure with congestion requiring SOC. The patient, in the opinion of the investigator, should be able to be treated for their symptoms without being admitted to the hospital. The planned 3-day hospitalization is to adequately manage any potential sign of hypotension and should not be required to treat the patient for the intensification of the diuretic therapy or same day IV loop diuretics. During the treatment period no new treatments for WHF should be initiated. This study will be conducted across approximately 8 centers in the US.
03

Conditions studied

  • Heart Failure
  • Worsening Heart Failure (WHF)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to give written , and able to follow instructions and comply with follow-up procedures.
  2. History of symptomatic HF (heart failure).
  3. Male or female ≥ 18 years of age at screening.
  4. Previous hospitalization for HF within the last 12 months prior to screening.
  5. Patients on optimal background therapy as per local practice for at least 30 days prior to screening and tolerating this well.
  6. Patients must present with at least 2 of the following signs / symptoms of

    WHF congestion:

    1. Dyspnea
    2. Orthopnea
    3. Fatigue
    4. Jugular venous distension
    5. Rales
    6. Edema
  7. Patient requires intensification (doubling the dose, adding another diuretic targeting another tubular segment) of oral diuretics, or IV diuresis for WHF as per Investigator at screening and treated as an outpatient patient.
  8. Estimated (eGFR) between 20 and 75 mL/ min/1.73 m2 (calculated using the CKD-EPI equation) at screening.
  9. NT-pro-BNP levels at screening:

    1. ≥ 1000 pg/mL for patients with ≤ 40%
    2. ≥ 700 pg/mL for patients with LVEF > 40%
    3. ≥ 1500 pg/mL for patients with current atrial fibrillation, regardless of LVEF. For patients with ≥ 30 kg/m2 the NT-pro-BNP values are lowered by 20%. The values are as follows:

    <!-- -->

    1. ≥ 800 pg/mL for patients with LVEF ≤ 40%
    2. ≥ 560 pg/mL for patients with LVEF > 40%
    3. ≥ 1200 pg/mL for patients with current atrial fibrillation, regardless of LVEF. The most recent LVEF value assessed in the 12 months prior to screening should be used.
  10. Systolic Blood Pressure (SBP) ≥ 105 mmHg at screening.
  11. Willing and able to stay in the clinic for observation/monitoring for 3 days.
  12. Willing to self-administer all SC injections.

Exclusion criteria

Exclusion Criteria:

  1. Patients with blood pressure > 180 mmHg or persistent heart rate > 130 bpm at Screening.
  2. History of symptomatic hypotension.
  3. History of orthostatic hypotension.
  4. Temperature > 38.5°C (oral or equivalent) or sepsis or active infection requiring antimicrobial treatment.
  5. Clinical evidence of acute coronary syndrome (ACS) currently or within 30 days prior to Screening.
  6. Acute Heart Failure (AHF) due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate \< 45 bpm or atrial fibrillation/flutter with sustained ventricular response of > 130 bpm.
  7. The daily use of IV or oral (including but not limited to the use of IV or oral steroids for respiratory disorders or ). Note, inhaled steroids are allowed.
  8. IV antimicrobial treatment for sepsis or active infection.
  9. Patients with severe renal impairment defined at Screening \< 20 mL/min/1.73m2 (calculated using the CKD-EPI Equation), and/or those receiving current or planned dialysis or ultrafiltration.
  10. Patients with \< 10 g/dL, or a history of blood transfusion within the 14 days prior to screening, or active life-threatening gastrointestinal bleeding.
  11. Known hepatic impairment (as evidenced by total > 3 mg/dL, or increased ammonia levels, if performed) or history of cirrhosis with evidence of portal hypertension such as varices.
  12. Significant, uncorrected, left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area \< 1.0 cm2 or mean gradient > 40 mmHg on echocardiogram), and/or severe mitral stenosis.
  13. Severe aortic insufficiency or severe mitral regurgitation for which surgical or percutaneous intervention is indicated.
  14. Documented, prior to or at the time of screening, restrictive amyloid myocardiopathy, or acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy.
  15. Any major solid organ transplant recipient or planned/ anticipated organ transplant within 1 year.
  16. Major surgery, including implantable devices (e.g., implantable cardioverter defibrillator, cardiac resynchronization therapy), or major neurologic event including cerebrovascular events, within 30 days prior to screening.
  17. History of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past year with a current less than 1 year due to the malignancy.
  18. Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception and until the termination of gestate, confirmed by a positive human chorionic gonadotropin laboratory test.
  19. Use of other drugs within 30 days prior to Screening.
  20. History of known /prior exposure to R2R01 or serelaxin.
  21. Any other medical condition(s) that might put the patient at risk or influence study results in the Investigator's opinion, or that the Investigator deems unsuitable for the study including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders sufficient to interfere with the patient's ability to understand and comply with the protocol instructions or follow-up procedures.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
33 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    8 study subjects will receive placebo once daily subcutaneous injection for 7 days.

    Drug: Placebo

  • Experimental
    5.0 mg R2R01

    8 study subjects will receive 5.0 mg R2R01 once daily subcutaneous injection for 7 days.

    Drug: R2R01

  • Experimental
    7.5 mg R2R01

    8 study subjects will receive 7.5 mg R2R01 once daily subcutaneous injection for 7 days.

    Drug: R2R01

  • Experimental
    10.0 mg R2R01

    8 study subjects will receive 10.0 mg R2R01 once daily subcutaneous injection for 7 days.

    Drug: R2R01

Interventions

  • DrugPlacebo

    Matching placebo SC injection

  • DrugR2R01

    Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.

06

What researchers measure

Primary outcomes

  1. Number and rate of patients with one or more TEAEs (treatment emergent AE's) and/or serious TEAEs as assessed by CTCAE v5.0.

    To assess the safety and tolerability of various dose levels of R2R01 in WHF patients at Day 7 and Day 30.

    Time frame: Day 7, Day 30

  2. Number and rate of patients with one or more TEAEs (treatment emergent AE's) and/or serious TEAEs as assessed by CTCAE v5.0.

    To select the appropriate dose for Study R2R01-WHF-202

    Time frame: Day 30

Secondary outcomes

  1. Change from Baseline on NT-pro-BNP using descriptive and summary statistics by dose level at Day 7 and Day 30.

    To evaluate the effect of R2R01 on NT-pro-BNP as a proxy for cardiac congestion at Day 7 and Day 30.

    Time frame: Day 7, Day 30

  2. Change from baseline on Cystatin C and creatinine clearance using descriptive and summary statistics by dose level at Day 7 and Day 30.

    To evaluate the effect of R2R01 on Cystatin C and creatinine clearance (eGFR using CKD-EPI Equation using both creatinine and cystatin C) at Day 7 and Day 30.

    Time frame: Day 7, Day 30

  3. Number of patients requiring dose adjustment of oral diuretics during the 30-day follow-up.

    To evaluate the effect of R2R01 on therapy with diuretics at Day 30.

    Time frame: Day 30

  4. Number of patients with an event of: WHF-induced SDAC or other outpatient clinic visits requiring additional intensification of the therapy/IV loop diuretics using descriptive and summary statistics for change from baseline by dose level at Day 30.

    To evaluate the effect of R2R01 at Day 30 on: WHF-induced Same Day Access Clinic (SDAC)--or other outpatient clinic visits requiring, additional intensification of the therapy/IV loop diuretics.

    Time frame: Day 30

  5. Number of cardiovascular hospitalizations among patients using descriptive and summary statistics for change from baseline by dose level at Day 30.

    To evaluate the effect of R2R01 at Day 30 on: Cardiovascular (CV) hospitalizations.

    Time frame: Day 30

  6. Number of all-cause hospitalizations among patients using descriptive and summary statistics for change from baseline by dose level at Day 30.

    To evaluate the effect of R2R01 at Day 30 on: All-cause hospitalizations.

    Time frame: Day 30

  7. Number of patients with CV mortality using descriptive and summary statistics for change from baseline by dose level at Day 30.

    To evaluate the effect of R2R01 at Day 30 on: CV mortality.

    Time frame: Day 30

  8. Number of patients with all-cause mortality using descriptive and summary statistics for change from baseline by dose level at Day 30.

    To evaluate the effect of R2R01 at Day 30 on: All-cause mortality.

    Time frame: Day 30

07

Study locations

8 sites
  • Thomas Hospital
    Fairhope, Alabama 36532, United States
  • C&R Research
    Fort Meyers, Florida 33919, United States
  • C&R Research
    Hialeah, Florida 33013, United States
  • Encore Clinical Research
    Inverness, Florida 34452, United States
  • Encore Clinical Research
    Jacksonville, Florida 32216, United States
  • Amavita Clinical Research
    Miami, Florida 33137, United States
  • Lake Country
    Eatonton, Georgia 31024, United States
  • J&S Studies
    College Station, Texas 77845, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Nov 2024, 8 months.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 8 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2024
First posted
Feb 16, 2024
StartActual
Mar 1, 2024
Primary completionActual
Nov 4, 2024
CompletionActual
Nov 25, 2024
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06264310
Lead sponsor
River 2 Renal Corp.
Collaborators
International HealthCare, LLC
Responsible party
Sponsor
First posted
Feb 16, 2024
Start date
Mar 1, 2024
Primary completion
Nov 4, 2024
Completion
Nov 25, 2024
Last update
Jun 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion